Literature DB >> 21628416

Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD.

William B Clark1, Kristin D Brown-Gentry, Dana C Crawford, Kang-Hsien Fan, Jennifer Snavely, Heidi Chen, Bipin N Savani, Adetola Kassim, John P Greer, Friedrich G Schuening, Brian G Engelhardt, Madan H Jagasia.   

Abstract

B-cell activating factor (BAFF) single nucleotide polymorphisms (SNPs) are associated with autoimmune diseases. Because patients with classic and overlap chronic GVHD (cGVHD) have features of autoimmune diseases, we studied the association of recipient and/or donor BAFF SNPs with the phenotype of GVHD after allogeneic stem cell transplantation. Twenty tagSNPs of the BAFF gene were genotyped in 164 recipient/donor pairs. GVHD after day 100 occurred in 124 (76%) patients: acute GVHD (aGVHD) subtypes (n = 23), overlap GVHD (n = 29), and classic cGVHD (n = 72). In SNP analyses, 9 of the 20 tag SNPs were significant comparing classic/overlap cGVHD versus aGVHD subtypes/no GVHD. In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD. This study shows that genetic variation of BAFF modulates GVHD phenotype after allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628416     DOI: 10.1182/blood-2010-09-310011

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

2.  B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality.

Authors:  R M Saliba; S Sarantopoulos; C L Kitko; A Pawarode; S C Goldstein; J Magenau; A M Alousi; T Churay; H Justman; S Paczesny; P Reddy; D R Couriel
Journal:  Bone Marrow Transplant       Date:  2017-05-08       Impact factor: 5.483

Review 3.  Clinical applications for biomarkers of acute and chronic graft-versus-host disease.

Authors:  John E Levine; Sophie Paczesny; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

4.  Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation.

Authors:  Isabel Legaz; Manuel Muro; Rafael Alfaro; Santiago Llorente; Pedro Martinez; Víctor Jimenez-Coll; Helios Martínez-Banaclocha; José Antonio Galián; Carmen Botella; María Rosa Moya-Quiles; Jesús de la Peña-Moral; Alfredo Minguela
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-09-22       Impact factor: 3.831

5.  Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Authors:  Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

6.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

Authors:  Corey Cutler; Haesook T Kim; Bhavjot Bindra; Stefanie Sarantopoulos; Vincent T Ho; Yi-Bin Chen; Jacalyn Rosenblatt; Sean McDonough; Phandee Watanaboonyongcharoen; Philippe Armand; John Koreth; Brett Glotzbecker; Edwin Alyea; Bruce R Blazar; Robert J Soiffer; Jerome Ritz; Joseph H Antin
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

Review 7.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

Review 8.  Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.

Authors:  C Fiuza-Luces; R J Simpson; M Ramírez; A Lucia; N A Berger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 9.  Role of non-HLA gene polymorphisms in graft-versus-host disease.

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.490

10.  Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases.

Authors:  Jiunn-Diann Lin; Shun-Fa Yang; Yuan-Hung Wang; Wen-Fang Fang; Ying-Chin Lin; Yuh-Feng Lin; Kam-Tsun Tang; Mei-Yi Wu; Chao-Wen Cheng
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.